Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

Slides:

Advertisements

Similar presentations

The use of ERA after SERAPHIN, COMPASS-2 and AMBITION

Advertisements

Upfront Combination Therapy vs Step-Up Approach for PAH:

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Practical Recommendations for COPD:

Exploring Early Combination Therapy in PAH

Monitoring and Modifying Treatment in PAH

Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

NOACs In Long-term VTE Treatment: A State Of The Art Review

A Paradigm Shift in PAH.

An Update on Oral Prostanoids: Advancing Care for PAH?

The Clinical Enigma of Cardiogenic Shock

Optimizing Use of Biological Agents in Ulcerative Colitis

UNDERSTANDING RISK STRATIFICATION IN PAH:

MANAGING GLAUCOMA:.

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

The Latest Data on Oral Prostacyclin Therapy in PAH

Managing Complex Hypertension: What Every Physician Should Know

How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients

Managing Hard-To-Treat Hypertension: What Every Physician Should Know

All About PAH:.

When Would You Use Single Inhaler Triple Therapy in COPD?

PAH in Adults CHEST Guideline and Expert Panel Report: Grading of Evidence

Updates in Pulmonary Arterial Hypertension

Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy

Pharmacist Perspectives on Novel Agents in Multiple Myeloma

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

Program Overview. Treatment Options for Post-MI patients with LVD – are all ACE Inhibitors Equal?

Treatment of HR+ Breast Cancer: A Clinical Update

WHO Clinical Classification of PH Complex Cases in PH.

Evolving Science of PAH Treatment

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Risk Assessment in PAH.

Examining the Latest Evidence in PAH

Translating the Latest and Greatest Advances in PAH Into Clinical Practice.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Oral Prostanoids and PAH

Navigating Treatment Options in PAH

Preventing Clinical Events in PAH

What's New in Therapeutic Options for Moderate to Severe RA?

New Classes of Therapy in Multiple Myeloma

PAH-Related Morbidity as a Predictor of Mortality

Non-Chemotherapy Combinations in CLL

Pulmonary Arterial Hypertension and Connective Tissue Disease

What's New in PAH?.

PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH

Oral Prostacyclin Pathway Agents in PAH

Group 1 PAH: Current Therapies

Pulmonary Hypertension Updates From 2018

Incorporating Prostacyclins Into Practice

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Perspective on the Multidisciplinary Management of PAH

Patient Stories in PAH: Sequential Therapy in a FC II Patient

Assessing the Burden of Hyperkalemia

Optimal Treatment of PAH

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

Prostacyclin Pathway Agents in Action

Assessing the Burden of Hyperkalemia

Addressing Cardiovascular Events:

Incorporating New PAH Treatments Into Clinical Practice

PAH Pathways: What Do the Data Tell Us?”

Binge Eating Disorder.

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Optimizing Treatment of Refractory Gout

What's New in PAH?.

Practical Recommendations for COPD:

My PAH Patient.

Risk Stratification in MDS

Presentation transcript:

Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

Program Goals

PAH Challenges Remain in 2016

Pharmacologic Agents for PAH 3 Pathways

Evidence-Based Guidelines

Risk Stratification

Treatment Algorithm for PAH

Monotherapy Recommendations for PAH

Initial Combination Therapy Recommendations for PAH

The Rationale for Combination Therapy

Recommendations for Sequential Combination Therapy

SERAPHIN Placebo vs Macitentan 3 mg vs Macitentan 10 mg (1:1:1)

Incident and Prevalent Treatment-Naïve Cohorts From SERAPHIN

What Can We Learn From the Treatment Naïve Patients in SERAPHIN?

In Conclusion

Abbreviations

Abbreviations